Pathological analysis after neoadjuvant chemoradiotherapy for esophageal carcinoma: The Rotterdam experience

Journal of Surgical Oncology

Volumn 100, Issue 1, 2009, Pages 32-37

  Van Meerten, E ^a   Van Der Gaast, A ^a   Tilanus, H W ^a   Poley, J W ^a   Muller, K ^a   Van Dekken, H ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

Author keywords

Combined modality treatment; Esophageal cancer; Esophagectomy; Neoadjuvant chemoradiotherapy; Pathological analysis

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ASSESSMENT; CONTROLLED STUDY; ESOPHAGUS BIOPSY; ESOPHAGUS CARCINOMA; FEMALE; GASTROINTESTINAL ENDOSCOPY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR REGRESSION; ADJUVANT THERAPY; AGED; ESOPHAGUS TUMOR; LYMPH NODE METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY;

ADULT; AGED; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY;

EID: 67649392518     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21295     Document Type: Article

References (31)

1. Mandard AM, Dalibard F, Mandard JC, et al.: Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 1994;73:2680-2686.
2. Junker K, Thomas M, Schulmann K, et al.: Tumour regression in non-small-cell lung cancer following neoadjuvant therapy. Histological assessment. J Cancer Res Clin Oncol 1997;123:469-477. (Pubitemid 27436005)
3. Dworak O, Keilholz L, Hoffmann A: Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 1997;12:19-23. (Pubitemid 27138353)
4. Dunne B, Reynolds JV, Mulligan E, et al.: A pathological study of tumour regression in oesophageal adenocarcinoma treated with preoperative chemoradiotherapy. J Clin Pathol 2001;54:841-845. (Pubitemid 33063489)
5. Becker K, Mueller JD, Schulmacher C, et al.: Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 2003;98:1521-1530. (Pubitemid 37151509)
6. Bollschweiler E, Baldus SE, Schroder W, et al.: Staging of esophageal carcinoma: Length of tumor and number of involved regional lymph nodes. Are these independent prognostic factors? J Surg Oncol 2006;94:355-363.
7. Roder JD, Busch R, Stein HJ, et al.: Ratio of invaded to removed lymph nodes as a predictor of survival in squamous cell carcinoma of the oesophagus. Br J Surg 1994;81:410-413. (Pubitemid 24124822)
8. Brucher BL, Becker K, Lordick F, et al.: The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas. Cancer 2006;106:2119-2127. (Pubitemid 43673232)
9. Hofstetter W, Swisher SG, Correa AM, et al.: Treatment outcomes of resected esophageal cancer. Ann Surg 2002;236:376-384;discussion 384-1375
10. Berger AC, Farma J, Scott WJ, et al.: Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol 2005;23:4330-4337. (Pubitemid 46207006)
11. Schneider PM, Baldus SE, Metzger R, et al.: Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: Implications for response classification. Ann Surg 2005;242:684-692. (Pubitemid 41567124)
12. Chirieac LR, Swisher SG, Ajani JA, et al.: Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer 2005;103:1347-1355. (Pubitemid 40410728)
13. Rohatgi PR, Swisher SG, Correa AM, et al.: Histologic subtypes as determinants of outcome in esophageal carcinoma patients with pathologic complete response after preoperatieve chemoradiotherapy. Cancer 2006;106:552-558. (Pubitemid 43157617)
14. van Meerten E, Muller K, Tilanus HW, et al.: Neoadjuvant concurrent chemoradiation with weekly paclitaxel and carboplatin for patients with oesophageal cancer: A phase II study. Br J Cancer 2006;94:1389-1394. (Pubitemid 43772271)
15. Sobin LW, Wittekind Ch: TNM classification of malignant tumours. New York: Wiley-Liss; 2002.
16. Wang KL, Yang Q, Cleary KR, et al.: The significance of neuroendocrine differentiation in adenocarcinoma of the esophagus and esophagogastric junction after preoperative chemoradiation. Cancer 2006;107:1467-1474. (Pubitemid 44546905)
17. Shia J, Tickoo SK, Guillem JG, et al.: Increased endocrine cells in treated rectal adenocarcinomas: A possible reflection of endocrine differentiation in tumor cells induced by chemotherapy and radiotherapy. Am J Surg Pathol 2002;26:863-872. (Pubitemid 34747638)
18. Walsh TN, Noonan N, Hollywood D, et al.: A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996;335:462-467. (Pubitemid 26269945)
19. Burmeister BH, Smithers BM, Gebski V, et al.: Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: A randomised controlled phase III trial. Lancet Oncol 2005;6:659-668. (Pubitemid 41222756)
20. Urba SG, Orringer MB, Turrisi A, et al.: Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 2001;19:305-313. (Pubitemid 32112841)
21. Bosset JF, Gignoux M, Triboulet JP, et al.: Chemoradiotherapy followed by surgery compared with surgery alone in squamouscell cancer of the esophagus. N Engl J Med 1997;337:161-167. (Pubitemid 27306287)
22. Rice TW, Blackstone EH, Adelstein DJ, et al.: N1 esophageal carcinoma: The importance of staging and downstaging. J Thorac Cardiovasc Surg 2001;121:454-464. (Pubitemid 32230213)
23. Vogel SB, Mendenhall WM, Sombeck MD, et al.: Downstaging of esophageal cancer after preoperative radiation and chemotherapy. Ann Surg 1995;221:685-693; discussion 693-1685
24. Yano M, Yasuda T, Miyata H, et al.: Correlation between histological effects on the main tumors and nodal status after chemoradiotherapy for squamous cell carcinoma of the esophagus. J Surg Oncol 2005;89:244-250; discussion 250. (Pubitemid 40333532)
25. Prenzel KL, Konig A, Schneider PM, et al.: Reduced incidence of nodal micrometastasis after major response to neoadjuvant chemoradiation in locally advanced esophageal cancer. Ann Surg Oncol 2007;14:954-959. (Pubitemid 46175347)
26. Rohatgi P, Swisher SG, Correa AM, et al.: Characterization of pathologic complete response after preoperative chemoradiotherapy in carcinoma of the esophagus and outcome after pathologic complete response. Cancer 2005;104:2365-2372. (Pubitemid 41691557)
27. Gaca JG, Petersen RP, Peterson BL, et al.: Pathologic nodal status predicts disease-free survival after neoadjuvant chemoradiation for gastroesophageal junction carcinoma. Ann Surg Oncol 2006;13:340-346. (Pubitemid 43255917)
28. Gu Y, Swisher SG, Ajani JA, et al.: The number of lymph nodes with metastasis predicts survival in patients with esophageal or esophagogastric junction adenocarcinoma who receive preoperative chemoradiation. Cancer 2006;106:1017-1025. (Pubitemid 43297339)
29. Swisher SG, Hofstetter W, Wu TT, et al.: Proposed revision of the esophageal cancer staging system to accommodate pathologic response (pP) following preoperative chemoradiation (CRT). Ann Surg 2005;241:810-817; discussion 817-820.
30. Rizk NP, Venkatraman E, Bains MS, et al.: American Joint Committee on Cancer staging system does not accurately predict survival in patients receiving multimodality therapy for esophageal adenocarcinoma. J Clin Oncol 2007;25:507-512. (Pubitemid 350002956)
31. Law S, Kwong DL, Wong KH, et al.: The effects of neoadjuvant chemoradiation on pTNM staging and its prognostic significance in esophageal cancer. J Gastrointest Surg 2006;10:1301-1311. (Pubitemid 44781197)